来那度胺Revlimid,来那度胺说明书,来那度胺价格,香港来那度胺价格,来那度胺规格
【通用名称】
来那度胺Revlimid
【英文名称】
Revlimid(Lenalidomide hard capsules)
【中文名称】
瑞法纳，瑞复美（来那度胺胶囊）
销 商】 香港华特药房咨询：137-255-38-785.
部分英文Revlimid资料（仅供参考)
欧盟扩大来那度胺Revlimid的使用范围包括ASCT
regulators have expanded the scope of Celgene's Revlimid to include its use as
monotherapy for the maintenance treatment of adults with newly diagnosed multiple
myeloma who have undergone autologous stem cell transplantation (ASCT).
According to the firm, Revlimid (lenalidomide) is the first and only licensed treatment
in this setting and thus represents a major advance for those patients who tend
to be younger than the average patient with the incurable blood cancer.
For patients who are newly diagnosed with the condition and eligible for ASCT,
key treatment aims are to delay disease progression and achieve long-term control
over multiple myeloma. As such, these patients typically receive induction therapy
and high-dose chemotherapy with melphalan followed by ASCT.
&This treatment approach has been an established standard of care for over
20 years, but over half of patients who relapse do so within two to three years
of ASCT. Considering that over half of those patients who relapse do so within
2 to 3 years of ASCT, the approval of a maintenance therapy for use after ASCT
that may delay disease progression represents a major advance for these patients,&
Celgene said.
The decision to approve the drug was d on data from two cooperative group-led studies,
CALGB 1001049 and IFM 2005-02, which both had the primary efficacy endpoint of
progression-free survival (PFS) from transplant to the date of disease progression
In the CALGB 100104 trial, after 81.6 months of follow up, median PFS was 56.9
months in the Revlimid arm and 29.4 months in the placebo arm. In the IFM 2005-02
study, after 96.7 months of follow up, median PFS was 44.4 months in the Revlimid
arm versus 23.8 months in the placebo arm.
&We now have an opportunity to enhance immune function and delay disease progression
by controlling residual malignant cells and slowing tumour growth,& said Professor
Michel Attal, executive director of the Institut Universitaire du Cancer Toulouse
Oncopole and Institut Claudius Regaud, France.
&Revlimid has been shown to increase progression-free survival after ASCT
in clinical trials. Having a licensed therapy for use in this very important setting
means we now have the opportunity to delay disease progression by sustaining the
response&.
Around 39,000 people are diagnosed with multiple myeloma and 24,000 die from it
in Europe every year.
Revlimid is also approved as combination therapy for the treatment of patients
not eligible for transplant who are newly diagnosed or those have received at least
one prior therapy.
相关链接：来那度胺Revlimid,来那度胺在哪里有买,来那度胺价格,来那度胺怎么购买,来那度胺说明书,来那度胺规格-香港华特药业官网
楼主邀你扫码
参与上面帖子讨论
你尚未登录或可能已退出账号:(请先或者
【敬请阅读】
亲爱的网友们，、有更新哦！
请您务必审慎阅读、充分理解各条款内容，特别是免除或者限制责任的条款、法律适用和争议解决条款。免除或者限制责任将以粗体标识，您应重点阅读。
【特别提示】
如您继续使用我们的服务，表示您已充分阅读、理解并接受《西祠站规》、《西祠胡同用户隐私保护政策》的全部内容。阅读《西祠站规》、《西祠胡同用户隐私保护政策》的过程中，如果您有任何疑问，可向平台客服咨询。如您不同意《西祠站规》、《西祠胡同用户隐私保护政策》的任何条款，可立即停止使用服务。
南京西祠信息技术股份有限公司
我已阅读并同意、中的全部内容！18来那度胺机制-第2页
上亿文档资料，等你来发现
18来那度胺机制-2
S18F.Davies,R.Baz/BloodR；5.In?uenceofdexamethason；Recentevidencesuggeststh；These?ndingsmayhelptoexp；Alternatively,patientsma；Currentavailabledatasugg；withoutantagonizinglenal；DrDav
S18F.Davies,R.Baz/BloodReviews24(5.In?uenceofdexamethasoneonthedualeffectsoflenalidomideRecentevidencesuggeststhatcoadministrationofdexamethasonemayalterthedualeffectsoflenalidomide.9,14,16,17Asmentioned,lenalidomideincombinationwithdexamethasonesynergisticallyinhibitsmyelomacellgrowth,activatescaspases,andinducesapoptosis,14enhancingthetumoricidaleffectsoflenalidomide.However,dexamethasoneappearstoantagonizetheimmune-enhancingeffectoflenalidomidebyinhibitingtheT-andNK-cellcostimulatoryeffectsoflenalidomide.14Speci?cally,dexamethasoneinhibitedlenalidomide-enhancedIL-2productioninprimaryhumanTcells,andinhibitedlenalidomide-mediatedIFN-gandgranzymeBproductioninprimaryhumanNKcellsinadose-dependentmannerinvitro.14These?ndingsmayhelptoexplaintheresultsoftherecentphaseIIItrialinpatientswithnewlydiagnosedMMbyRajkumaretal.,wherelow-dosedexamethasonepluslenalidomidedemonstratedabene?tinearlyOScomparedwithpatientswhoreceivedlenalidomideplushigh-dosedexamethasone.32One-yearOSwas96%(95%CI94C99)inthelow-dosegroupcomparedwith87%(95%CI82C92)inthehigh-dosegroup,and2-yearOSwas87%(95%CI81C93)and75%(95%CI68C93),respectively.Takentogether,resultsfromthepreclinicalstudiesandclinicaltrialsuggestthataregimenoflenalidomidepluslow-dosedexamethasonemayresultinthebestclinicalactivitybyprovidingsynergisticantiproliferativeeffects,butwithoutaffectingtheimmunomodulatoryeffectsoflenalidomide.14AnalternativeexplanationfortheprolongedOSwiththelowerdoseofdexamethasonecouldberelatedtothetolerabilitypro?le.Alowerdosewouldbeassociatedwithabettersafetypro?le,whichmayallowlongertreatmentexposure.Alternatively,patientsmaybene?tfromreceivinglenalidomidealoneorindependentofcorticosteroids.ArecentretrospectivestudyevaluatedtheactivityoflenalidomidemonotherapyinnewlydiagnosedMM.66In17patientstreatedwithlenalidomidewithoutcorticosteroids,theORRwas47%atamedianfollow-upof7months(range1C26).Themediantimeto?rstresponsewas50days(range28C98)andmediantimetobestresponsewas69days(range30C591).Basedonthesepositive?ndings,aphaseIItrialhasbeeninitiatedtoinvestigatetheroleofaresponse-adaptedapproachusingsingle-agentlenalidomideasprimarytherapyforolderpatientswithnewlydiagnosedstandard-riskMM(ClinicalTrials.govidenti?er:NCT.ConclusionsCurrentavailabledatasuggestMMrequirescontinuoustherapytoreducetumorburdenandprolongsurvival.Lenalidomidehastheattributesofanagentthattargetsbothtumorgrowthandconcomitantimmunosuppression,whilebeingwelltoleratedandconvenientforlong-termuse.Lenalidomidehaspotenttumoricidalandimmunomodulatoryeffectsonmyelomacellsandtheirmicroenvironment,whicharethoughttoresultinbothrapidandsustainedcontrolofMMintheclinic.Lenalidomide,incombinationwithdexamethasone,isactiveandgenerallywelltoleratedintherelapsed/refractoryMMsettingandthereisevidencethatcontinuoustreatmentwithlenalidomidemayimproveclinicalresponse.Furthermore,lenalidomideappearstobeeffectiveregardlessofpriorthalidomidetreatment,whichmayre?bined?ndingsfrompreclinicalandclinicalstudiesalsoprovideinsightsintohowtheuseofconcomitantlenalidomideanddexamethasonecanbefurtheroptimized.Theuseoflow-dosedexamethasonemayprovidesynergisticantiproliferativeeffectswithoutantagonizinglenalidomide-mediatedimmuneeffects,whichmayexplaintheearlysurvivalbene?tobservedcomparedwithhigh-dosedexamethasone.Aspreclinicalandclinicalresearchcontinues,additionalinsightsintothedualmechanismofactionoflenalidomidewillbeobtained,whichmayhelptofurthermaximizetheuseoflenalidomideinthetreatmentofMM.7.Con?ictofinterestDrDavieshasservedontheSpeakersBureauforCelgeneCorporationandOrthoBiotechandhasparticipatedinAdvisoryBoardsforCelgene,OrthoBiotech,andNovartis.DrBazhasparticipatedinAdvisoryBoardsfor,andhasreceivedresearchfundingfrom,CelgeneCorporation.AcknowledgementsTheauthorsreceivededitorialsupportfromExcerptaMedicainthepreparationofthismanuscript,fundedbyCelgeneCorporation.Theauthorsarefullyresponsibleforcontentandeditorialdecisionsforthismanuscript.References1.MatsuiW,WangQ,BarberJP,etal.Clonogenicmultiplemyelomaprogenitors,stemcellproperties,anddrugresistance.CancerResC7.2.CookG,CampbellJD.Immuneregulationinmultiplemyeloma:thehost-tumourcon?ict.BloodRevC62.3.Schutt¨P,BrandhorstD,StellbergW,etal.Immuneparametersinmultiplemyelomapatients:in?uenceoftreatmentandcorrelationwithopportunisticinfections.LeukLymphoma0C82.4.AttalM,HarousseauJL,LeyvrazS,etal.Maintenancetherapywiththalidomideimprovessurvivalinpatientswithmultiplemyeloma.Blood9C94.5.Chanan-KhanAA,ChesonBD.LenalidomideforthetreatmentofB-cellmalignancies.JClinOncol4C52.6.KotlaV,GoelS,NischalS,etal.Mechanismofactionoflenalidomideinhematologicalmalignancies.JHematolOncol.7.ChungF,LuJ,PalmerBD,etal.Thalidomidepharmacokineticsandmetaboliteformationinmice,rabbits,andmultiplemyelomapatients.ClinCancerRes9C56.8.ChenN,LauH,KongL,etal.Pharmacokineticsoflenalidomideinsubjectswithvariousdegreesofrenalimpairmentandinsubjectsonhemodialysis.JClinPharmacol6C75.9.HideshimaT,ChauhanD,ShimaY,etal.Thalidomideanditsanalogsovercomedrugresistanceofhumanmultiplemyelomacellstoconventionaltherapy.Blood3C50.10.CorralLG,HaslettPA,MullerGW,etal.DifferentialcytokinemodulationandTcellactivationbytwodistinctclassesofthalidomideanaloguesthatarepotentinhibitorsofTNF-alpha.JImmunolC6.11.LuL,PayvandiF,WuL,etal.Theanti-cancerdruglenalidomideinhibitsangiogenesisandmetastasisviamultipleinhibitoryeffectsonendothelialcellfunctioninnormoxicandhypoxicconditions.MicrovascResC86.12.Revlimid?(lenalidomide).Prescribinginformation.CelgeneCorporation,Summit,NJ./pdf/REVLIMID_PI.pdf.13.HideshimaT,ChauhanD,PodarK,SchlossmanRL,RichardsonP,AndersonKC.Noveltherapiestargetingthemyelomacellanditsbonemarrowmicroenviron-ment.SeminOncolC12.14.GandhiAK,KangJ,CaponeL,etal.Dexamethasonesynergizeswithlenalidomidetoinhibitmultiplemyelomatumorgrowth,butreduceslenalidomide-inducedimmunomodulationofTandNKcellfunction.CurrCancerDrugTargetsC67.15.MitsiadesN,MitsiadesCS,PoulakiV,etal.Apoptoticsignalinginducedbyimmunomodulatorythalidomideanalogsinhumanmultiplemyelomacells:therapeuticimplications.Blood5C30.16.SchaferPH,GandhiAK,ZhangLH,etal.Opposingeffectsofdexamethasoneonlenalidomideactivityinmultiplemyeloma:additive/synergisticeffectsonanti-proliferativeactivityonmyelomacellsandantagonisticeffectsonimmunefunction[abstract].Blood:Abstract2761.17.SchaferPH,GandhiAK,ZhangLH,etal.Opposingeffectsofdexamethasoneonlenalidomideactivityinmultiplemyeloma[abstract].ClinLymphMyelomaSuppl2009;9(Suppl1):AbstractB444.18.VerhelleD,CorralLG,WongK,etal.LenalidomideandCC-4047inhibittheproliferationofmalignantBcellswhileexpandingnormalCD34+progenitorcells.CancerResC55.19.DamianoJS,CressAE,HazlehurstLA,ShtilAA,DaltonWS.Celladhesionmediateddrugresistance(CAM-DR):roleofintegrinsandresistancetoapoptosisinhumanmyelomacelllines.Blood8C67.F.Davies,R.Baz/BloodReviews24(S1920.ShainKH,YardeDN,MeadsMB,etal.Beta1integrinadhesionenhancesIL-6-mediatedSTAT3signalinginmyelomacells:implicationsformicroenvironmentin?uenceontumorsurvivalandproliferation.CancerRes9C15.21.RaabMS,PodarK,BreitkreutzI,RichardsonPG,AndersonKC.Multiplemyeloma.LancetC39.22.DankbarB,Padro′T,LeoR,etal.Vascularendothelialgrowthfactorandinterleukin-6inparacrinetumor-stromalcellinteractionsinmultiplemyeloma.Blood0C6.23.GuptaD,TreonSP,ShimaY,etal.Adherenceofmultiplemyelomacellstobonemarrowstromalcellsupregulatesvascularendothelialgrowthfactorsecretion:therapeuticapplications.Leukemia0C61.24.ChauhanD,KharbandaS,OgataA,etal.Interleukin-6inhibitsFas-inducedapoptosisandstress-activatedproteinkinaseactivationinmultiplemyelomacells.BloodC34.25.TaiYT,FulcinitiM,HideshimaT,etal.TargetingMEKinducesmyeloma-cellcytotoxicityandinhibitsosteoclastogenesis.Blood6C63.26.LonialS,VijR,HarousseauJ,etal.Elotuzumabincombinationwithlenalidomideandlow-dosedexamethasoneinrelapsedorrefractorymultiplemyeloma:aphaseI/IIstudy[abstract].JClinOncols):Abstract8020.27.ListA,DewaldG,BennettJ,etal.Lenalidomideinthemyelodysplasticsyndromewithchromosome5qdeletion.NEnglJMed6C65.28.Escoubet-LozachL,LinIL,Jensen-PergakesK,etal.Pomalidomideandlenalidomideinducep21WAF-1expressioninbothlymphomaandmultiplemyelomathroughaLSD1-mediatedepigeneticmechanism.CancerRes7C56.29.PalumboA,FalcoP,CorradiniP,etal.Melphalan,prednisone,andlenalidomidetreatmentfornewlydiagnosedmyeloma:areportfromtheGIMEMA-ItalianMultipleMyelomaNetwork.JClinOncol9C65.30.PalumboA,DimopoulosMA,DelforgeM,etal.Aphase3studytodeterminetheef?cacyandsafetyoflenalidomidecombinedwithmelphalanandprednisoneinpatients≥65yearswithnewlydiagnosedmultiplemyeloma(NDMM)[abstract].Haematologica2010;95(Suppl2):Abstract0566.31.NiesvizkyR,JayabalanDS,ChristosPJ,etal.BiRD(Biaxin[clarithromycin]/Revlimid[lenalidomide]/dexamethasone)combinationtherapyresultsinhighcomplete-andoverall-responseratesintreatment-naivesymptomaticmultiplemyeloma.Blood1C9.32.RajkumarSV,JacobusS,CallanderNS,etal.Lenalidomideplushigh-dosedexamethasoneversuslenalidomidepluslow-dosedexamethasoneasinitialtherapyfornewlydiagnosedmultiplemyeloma:anopen-labelrandomisedcontrolledtrial.LancetOncolC37.33.DimopoulosM,SpencerA,AttalM,etal.Lenalidomideplusdexamethasoneforrelapsedorrefractorymultiplemyeloma.NEnglJMed3C32.34.WeiselKC,H¨anelM,NiederwieserD,etal.Speedofresponsewithlenalidomideanddexamethasoneinpatientswithrelapsedorrefractorymultiplemyeloma:?rstresultsoftheMM-019Germancompassionateuseprotocol[abstract].Haematologica2009;94(Suppl2):Abstract0397.35.KnopS,GereckeC,LiebischP,etal.Lenalidomide,adriamycin,anddexamethasone(RAD)inpatientswithrelapsedandrefractorymultiplemyeloma:areportfromtheGermanMyelomaStudyGroupDSMM(DeutscheStudiengruppeMultiplesMyelom).Blood7C43.36.RichardsonPG,SonneveldP,SchusterMW,etal.Bortezomiborhigh-dosedexamethasoneforrelapsedmultiplemyeloma.NEnglJMed7C98.37.MorganGJ,ScheySA,WuP,etal.Lenalidomide(Revlimid),incombinationwithcyclophosphamideanddexamethasone(RCD),isaneffectiveandtoleratedregimenformyelomapatients.BrJHaematolC9.38.SanMiguelJF,SchlagR,KhuagevaNK,etal.Bortezomibplusmelphalanandprednisoneforinitialtreatmentofmultiplemyeloma.NEnglJMedC17.39.DimopoulosMA,ChenC,SpencerA,etal.Long-termfollow-uponoverallsurvivalfromtheMM-009andMM-010phaseIIItrialsoflenalidomideplusdexamethasoneinpatientswithrelapsedorrefractorymultiplemyeloma.Leukemia7C52.40.OrlowskiRZ,NaglerA,SonneveldP,etal.RandomizedphaseIIIstudyofpegylatedliposomaldoxorubicinplusbortezomibcomparedwithbortezomibaloneinrelapsedorrefractorymultiplemyeloma:combinationtherapyimprovestimetoprogression.JClinOncol2C901.41.WeberDM,ChenC,NiesvizkyR,etal.LenalidomideplusdexamethasoneforrelapsedmultiplemyelomainNorthAmerica.NEnglJMed3C42.42.DaviesFE,RajeN,HideshimaT,etal.Thalidomideandimmunomodulatoryderivativesaugmentnaturalkillercellcytotoxicityinmultiplemyeloma.BloodC6.43.HaslettPA,HanekomWA,MullerG,KaplanG.Thalidomideandathalidomideanaloguedrugcostimulatevirus-speci?cCD8+Tcellsinvitro.JInfectDisC55.44.WuL,AdamsM,CarterT,etal.Lenalidomideenhancesnaturalkillercellandmonocyte-mediatedantibody-dependentcellularcytotoxicityofrituximab-treatedCD20+tumorcells.ClinCancerRes0C7.45.ChangDH,LiuN,KlimekV,etal.Enhancementofligand-dependentactivationofhumannaturalkillerTcellsbylenalidomide:therapeuticimplications.BloodC21.46.LioznovM,El-CheikhJJr,HoffmannF,etal.Lenalidomideassalvagetherapyafterallo-SCTformultiplemyelomaiseffectiveandleadstoanincreaseofactivatedNK(NKp44(+))andT(HLA-DR(+))cells.BoneMarrowTransplantC53.47.BartlettJB,MichaelA,ClarkeIA,etal.PhaseIstudytodeterminethesafety,tolerabilityandimmunostimulatoryactivityofthalidomideanalogueCC-5013inpatientswithmetastaticmalignantmelanomaandotheradvancedcancers.BrJCancerC61.48.ReddyN,Hernandez-IlizaliturriFJ,DeebG,etal.Immunomodulatorydrugsstimulatenaturalkiller-cellfunction,altercytokineproductionbydendriticcells,andinhibitangiogenesisenhancingtheanti-tumouractivityofrituximabinvivo.BrJHaematolC45.49.TaiYT,LiXF,CatleyL,etal.Immunomodulatorydruglenalidomide(CC-5013,IMiD3)augmentsanti-CD40SGN-40-inducedcytotoxicityinhumanmultiplemyeloma:clinicalimplications.CancerRes12C20.50.ChiarenzaA,ParrinelloN,LaCavaP,etal.Lenalidomideisabletorestoreimmunesysteminmultiplemyelomapatients[abstract].Blood:Abstract4909.51.vanHeterenP,RenzO,Hahn-AstC,etal.Activationofinnateimmunityinpatientsreceivingcombinationtherapywithlenalidomide(Revlimid),cyclophosphamideandlow-dosedexamethasone(RCD)fornewlydiagnosedorrelapsed/refractorymyeloma[abstract].Haematologica2010;95(Suppl2):Abstract0352.52.NoonanKA,FergusonA,HuffCA,etal.TheimmunomodulatoryroleoflenalidomideonPrevnar?responsesinpatientswithrelapsedmultiplemeyloma:acomprehensiveanalysisoftheimmuneresponse[abstract].Blood:Abstract2772.53.BazR,DimopoulosM,RichardsonP,YuZ,HusseinM,Chanan-KhanA.Lenalidomide-basedtherapyleadstoimprovementofhumoralimmunesysteminrelapsedorrefractorymultiplemyelomapatientswhorespondtothetherapy[abstract].Haematologica2009;94(Suppl2):Abstract0395.54.NoonanKA,FergusonA,EmerlingA,etal.LenalidomideaugmentsimmuneresponsestoPrevnarvaccinationinrelapsedmyelomapatients:implicationsforcancerandinfectiousvaccines[abstract].Blood:Abstract1864.55.HarousseauJL,DimopoulosMA,WangM,etal.Betterqualityofresponsetolenalidomideplusdexamethasoneisassociatedwithimprovedclinicaloutcomesinpatientswithrelapsedorrefractorymultiplemyeloma.Haematologica8C44.56.SanMiguelJF,DimopoulosMA,StadtmauerEA,etal.Longerdurationoftreatmentandmaintenanceofbestresponsewithlenalidomideanddexamethasoneprolongsoverallsurvivalinpatientswithrelapsedorrefractorymultiplemyeloma[abstract].Blood:Abstract3702.57.AttalM,CristiniC,MaritG,etal.Lenalidomidemaintenanceaftertransplanta-tionformyeloma[abstract].JClinOncols):Abstract8018.58.McCarthyPL,OwzarK,AndersonKC,etal.PhaseIIIintergroupstudyoflenalidomideversusplacebomaintenancetherapyfollowingsingleautologousstemcelltransplant(ASCT)formultiplemyeloma(MM):CALGB100104[abstract].JClinOncols):Abstract8017.59.SanMiguelJF,DimopoulosM,WeberD,etal.Dexamethasonedoseadjustmentsseemtoresultinbetteref?cacyandimprovedtolerabilityinpatientswithrelapsed/refractorymultiplemyelomawhoaretreatedwithlenalidomide/dexamethasone(MM009/010sub-analysis)[abstract].Blood:Abstract2712.60.WangM,DimopoulosMA,ChenC,etal.Lenalidomideplusdexamethasoneismoreeffectivethandexamethasonealoneinpatientswithrelapsedorrefractorymultiplemyelomaregardlessofpriorthalidomideexposure.Blood5C51.61.MarkT,SternJ,FurstJR,etal.Stemcellmobilizationwithcyclophosphamideovercomesthesuppressiveeffectoflenalidomidetherapyonstemcellcollectioninmultiplemyeloma.BiolBloodMarrowTransplantC8.62.PalumboA,BenYehudaD,CavalloF,etal.AdequatemobilizationofCD34innewlydiagnosedmultiplemyelomapatientsreceivinglenalidomideinductiontherapy[abstract].Haematologica2009;94(Suppl2):Abstract0707.63.TalamoG,ClaxtonDF,EhmannWC,MierskiJ,RybkaW,IbrahinS.Effectofmobilizationchemotherapywithcyclophosphamideandetoposideonstemcellcollectionbylenalidomide[abstract].JClinOncols):Abstract7096.64.TarantoloSR,McSweeneyPA,MicallefIN,KleinLM,CalandraG,HuebnerD.Plerixaforcanpredictablymobilizehematopoieticstemcellsinpatientswithmultiplemyelomapreviouslytreatedwithlenalidomide[abstract].BiolBloodMarrowTransplant2009;15(Suppl1):Abstract91.65.GuglielmelliT,BringhenS,BerrutiA,etal.SequentialtherapywithIMiD’sinrelapsed-refractorymultiplemyelomapatients[abstract].Blood:Abstract2888.66.BazR,PatelM,Finley-OliverE,etal.Singleagentlenalidomideinnewlydiagnosedmultiplemyeloma:aretrospectiveanalysis.LeukLymphoma5C9.三亿文库包含各类专业文献、中学教育、文学作品欣赏、高等教育、行业资料、应用写作文书、幼儿教育、小学教育、外语学习资料、18来那度胺机制等内容。　
　3.2 来那度胺的作用机制 来那度胺主要通过抑制白介素、α 肿瘤坏死因子来发挥作用[6]。其具有:① 免疫调节作用:来那度胺可通过调整免疫系统中 T 细胞的激活... 　抗癌药来那度胺扩大适应症_医药卫生_专业资料。抗癌药来那度胺扩大适应症(来源:医药经济报) 2 月 18 日,FDA 批准扩大 Celgene 公司的抗癌药 Revlimid(来那度... 　中国来那度胺行业市场前景调查及投融资战略研究报告
年 前言 企业成功的关键就在于,能否跳出红海,开辟蓝海。那些成功的公司往往都会倾尽毕生 的精力及... 　17、试述吗啡和度冷丁在作用、应用上有何异同? 答...22、阿司匹林与氯丙嗪对体温的影响在机制、作用和...③甲氧苄胺嘧啶(TMP) :与磺胺嘧啶合用,起协同增效... 　1财富值 二聚氢胺 暂无评价 4页 免费 脂肪胺 暂无评价 14页 免费 来那度胺的临床应用进展 暂无评价 3页 2财富值 利_奈_唑_胺 暂无评价 10页 免费喜欢... 　它适宜用于先前至少已经接受过两种治疗药物,包括来那度胺 (lenalidomide)和硼替佐米(bortezomib) ,对治疗没有应答(未能奏效)和在最后一次治 疗后 60 天内进展(... 　Celgene 公司的 Revlimid(来那度胺)于 2005 年获得 FDA 批准,用于多发性骨髓 ...沙利度胺的临床新用途和... 3页 免费
沙利度胺的药理作用机制... 暂无评... 　来那度胺+地塞米松 环磷酰胺+来那度胺+地塞米松 美法仑+泼尼松+来那度胺 环磷酰胺+美司钠+长春新碱+多柔比星+地塞 HyperCVAD 米松 CTD 环磷酰胺+沙利度胺+...